1073-39-8Relevant articles and documents
Novel cross-linking monomer based on benzocyclobutene for an application in microelectronics
Levchenko,Adamov,Chudov,Shmelin,Kalashnikov, A. Yu.,Grebennikov
, p. 2396 - 2400 (2020)
A new cross-linking monomer, allyl-bis(benzocyclobuten-4-yl)methylsilane (ABCBMS), was synthesized and its physical properties were investigated. Copolymers of ABCBMS with triethylene glycol dimethacrylate (TGM-3) and bis(methacryloylethylene glycol) carbonate (BMCC-2) were obtained by photo- and thermal polymerization. The final cross-linking of the copolymers took place at 200 °C. Homo- and copolymers of ABCBMS, ABCBMS-TGM-3 (50: 50) and ABCBMS—BMCC-2 (50: 50) exhibit high thermal stability (Td5% = 460, 359, and 352 °C, respectively) and good dielectric properties (ε = 2.7–2.8 and tg δ = (3.7–6.7)?10?4 at 10 GHz).
Rodlike Tetracene Derivatives
Roth, Michael,Ahles, Marcus,Gawrisch, Christian,Schwalm, Thorsten,Schmechel, Roland,Melzer, Christian,von Seggern, Heinz,Rehahn, Matthias
, p. 13445 - 1345 (2017)
Efficient and versatile synthetic access to rodlike tetracene derivatives was developed by means of Diels–Alder cycloaddition, halogenation, halogen–metal exchange, and transition metal mediated coupling reactions. Herein, the synthesis and structural, electrical, and charge-transport properties of three of the resulting materials, namely, 2-(tetracen-2-yl)tetracene, 1,4-bis(2-tetracenyl)benzene, and 2,5-bis(2-tetracenyl)thiophene, are presented. Good crystallization behavior on SiO2 substrates, narrowing of the bandgap by 0.2 eV, and a decrease of the ionization potential of more than 0.5 eV compared to tetracene were observed. Charge-carrier field-effect mobilities on the order of 10?1 cm2 V?1 s?1, on/off ratios of 105, and threshold voltages Vth15 V were found in thin-film organic field-effect transistors prepared by standard high-vacuum deposition techniques.
ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS
-
Paragraph 0762, (2017/03/14)
Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, I" and I'" or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduces the excessive activation of complement.